PT - JOURNAL ARTICLE AU - Kawashima, Takahiko AU - Yamashita, Ayumu AU - Yoshihara, Yujiro AU - Kobayashi, Yuko AU - Okada, Naohiro AU - Kasai, Kiyoto AU - Huang, Ming-Chyi AU - Sawa, Akira AU - Yoshimoto, Junichiro AU - Yamashita, Okito AU - Murai, Toshiya AU - Miyata, Jun AU - Kawato, Mitsuo AU - Takahashi, Hidehiko TI - Generalisable functional imaging classifiers of schizophrenia have multifunctionality as trait, state, and staging biomarkers AID - 10.1101/2024.01.02.23300101 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.02.23300101 4099 - http://medrxiv.org/content/early/2024/05/06/2024.01.02.23300101.short 4100 - http://medrxiv.org/content/early/2024/05/06/2024.01.02.23300101.full AB - Schizophrenia spectrum disorder (SSD) is one of the top causes of disease burden; similar to other psychiatric disorders, SSD lacks widely applicable and objective biomarkers. This study aimed to introduce a novel resting-state functional connectivity (rs-FC) magnetic resonance imaging (MRI) biomarker for diagnosing SSD. It was developed using customised machine learning on an anterogradely and retrogradely harmonised dataset from multiple sites, including 617 healthy controls and 116 patients with SSD. Unlike previous rs-FC MRI biomarkers, this new biomarker demonstrated a notable accuracy rate of 77.3% in an independent validation cohort, including 404 healthy controls and 198 patients with SSD from seven different sites, effectively mitigating across-scan variability. Importantly, our biomarker specifically identified SSD, differentiating it from other psychiatric disorders. Our analysis identified 47 important FCs significant in SSD classification, several of which are involved in SSD pathophysiology. Beyond their potential as trait markers, we explored the utility of these FCs as both state and staging markers. First, based on aggregated FCs, we built prediction models for clinical scales of trait and/or state. Thus, we successfully predicted delusional inventory scores (r=0.331, P=0.0177), but not the overall symptom severity (r=0.128, P=0.178). Second, through comprehensive analysis, we uncovered associations between individual FCs and symptom scale scores or disease stages, presenting promising candidate FCs for state or staging markers. This study underscores the potential of rs-FC as a clinically applicable neural phenotype marker for SSD and provides actionable targets to neuromodulation therapies.Competing Interest StatementMK is an inventor of patents owned by the Advanced Telecommunications Research Institute International related to the present work (PCT/JP2014/061544 [WO2014178323] and JP2015-228970/6195329). AY and MK are inventors of a patent application submitted by the Advanced Telecommunications Research Institute International related to the present work (JP2018-192842).Funding StatementThis study was supported by KAKENHI JP (23H04979) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by AMED under Grant Numbers JP19dm0207069, JP18dm0307001, JP18dm0307004, JP18dm0307008, and JP18dm0307009, and by CREST (JPMJCR22P3) from the Japan Science and Technology Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Kyoto University, Showa University, Hiroshima University, and University of Tokyo gave ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.